|
|
 Previous Article | Table of Contents | Next Article 
A novel treatment of childhood lymphoblastic non-Hodgkin's lymphoma: early
and intermittent use of teniposide plus cytarabine
GV Dahl, G Rivera, CH Pui, J Mirro , J Ochs, DK Kalwinsky, M Abromowitch, AT Look and SB Murphy
We treated 24 children and adolescents with stage III or IV lymphoblastic
non-Hodgkin's lymphoma, using a protocol designed for patients with
poor-prognosis acute lymphoblastic leukemia (ALL). Early therapy consisted
of teniposide plus cytarabine administered before and immediately after
prednisone, vincristine, and asparaginase. The two- drug combination was
also given intermittently with continuous 6- mercaptopurine and
methotrexate during the first year of continuation chemotherapy. Periodic
intrathecal methotrexate and delayed cranial irradiation were used to
prevent central nervous system involvement. Anthracycline compounds,
alkylating agents, high-dose methotrexate, and involved-field irradiation
were not used in any phase of treatment. Twenty-two (96%) of the 23
evaluable patients achieved complete remission. With a median follow-up of
2 1/2 years, only four patients have relapsed; the remainder have been
disease-free for eight months to more than five years. The projected
four-year continuous complete remission rate is 73% for all patients and
79% for the 19 with mediastinal involvement at diagnosis. These results
demonstrate that use of teniposide plus cytarabine with an otherwise
conventional plan of ALL therapy is an effective approach to the treatment
of childhood lymphoblastic lymphoma.
Volume 66,
Issue 5,
pp. 1110-1114,
11/01/1985
Copyright © 1985 by The American Society of Hematology
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
N. L. Kobrinsky, R. Sposto, N. R. Shah, J. R. Anderson, C. DeLaat, M. Morse, P. Warkentin, G. S. Gilchrist, M. D. Cohen, D. Shina, et al.
Outcomes of Treatment of Children and Adolescents With Recurrent Non-Hodgkin's Lymphoma and Hodgkin's Disease With Dexamethasone, Etoposide, Cisplatin, Cytarabine, and L-Asparaginase, Maintenance Chemotherapy, and Transplantation: Children's Cancer Group Study CCG-5912
J. Clin. Oncol.,
May 1, 2001;
19(9):
2390 - 2396.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Reiter, M. Schrappe, W.-D. Ludwig, M. Tiemann, R. Parwaresch, M. Zimmermann, E. Schirg, G. Henze, G. Schellong, H. Gadner, et al.
Intensive ALL-type therapy without local radiotherapy provides a 90% event-free survival for children with T-cell lymphoblastic lymphoma: a BFM Group report
Blood,
January 15, 2000;
95(2):
416 - 421.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
J. T. Sandlund, J. R. Downing, and W. M. Crist
Non-Hodgkin's Lymphoma in Childhood
N. Engl. J. Med.,
May 9, 1996;
334(19):
1238 - 1248.
[Full Text]
[PDF]
|
|
|
|
|
